We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00380393
First Posted: September 26, 2006
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose

This phase IIb trial is being done to find out if the RTS,S/AS01 vaccine helps to prevent children from falling ill with malaria and to evaluate vaccine safety.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Condition Intervention Phase
Malaria Biological: GSK malaria vaccine 257049 Vaccine Biological: Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS,S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • First case of malaria meeting the primary case definition [ Time Frame: Over a period starting 14 days after Dose 3 and extending for 4 months. ]

Secondary Outcome Measures:
  • First case of malaria meeting the secondary case definition. [ Time Frame: Over a period starting 14 days after Dose 3 and extending for 4 months ]
  • Multiple events of malaria meeting the primary case definition. [ Time Frame: Over a period starting 14 days after Dose 3 and extending for 4 months. ]
  • Multiple events of malaria meeting the secondary case definition. [ Time Frame: Over a period starting 14 days after Dose 3 and extending for 4 months. ]
  • Parasite prevalence and density [ Time Frame: At 4½ months post Dose 3 ]
  • Haemoglobin [ Time Frame: At 4½ months post Dose 3. ]
  • Occurrence of solicited symptoms and local reactions. [ Time Frame: Over a 7-day follow-up period ]
  • Occurrence of unsolicited symptoms. [ Time Frame: Over a 30-day follow-up period (day of vaccination and 29 subsequent days) after each vaccination. ]
  • Occurrence of serious adverse events [ Time Frame: From the time of first vaccination (Month 0) until 4½ months post Dose 3 (Month 6½). ]
  • Occurrence of parameters of hematological monitoring outside acceptable ranges.
  • Antibody to the P. falciparum circumsporozoite (CS) repeat domain (anti-CS antibody) titers. [ Time Frame: Prior to vaccination, 1 month post Dose 3 and 4½ months post Dose 3 ]
  • Anti-hepatitis B surface antigen (anti-HBs) titers [ Time Frame: Prior to vaccination and 1 month post Dose 3. ]
  • Frequency of CD4+ and CD8+ CS-specific T-cells expressing at least 2 of the following: IL-2, CD40L, TNF-α and IFN-у. [ Time Frame: Prior to vaccination and 1 month post Dose 3. ]

Enrollment: 855
Study Start Date: January 3, 2007
Study Completion Date: November 11, 2008
Primary Completion Date: August 15, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A Biological: GSK malaria vaccine 257049 Vaccine
3 dose intramuscular injection
Other Names:
  • RTS
  • S/AS01E vaccine
Active Comparator: Group B Biological: Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine
3 dose intramuscular injection

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Months to 17 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A male or female child of between 5 months and 17 months of age at the time of first vaccination.
  • Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child..
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.

Exclusion Criteria:

  • Acute disease at the time of enrolment.
  • Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.
  • Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of acceptable limits.
  • Planned administration/administration of a vaccine not foreseen by the study within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid or scheduled diphtheria, pertussis or measles vaccine.
  • Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose
  • Previous participation in any other malaria vaccine trial.
  • Simultaneous participation in any other clinical trial.
  • Same sex twin.
  • History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00380393


Locations
Kenya
GSK Investigational Site
Kilifi, Kenya, 80108
Tanzania
GSK Investigational Site
Amani, Tanga, Tanzania
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Additional Information:
Publications:

Study Data/Documents: Dataset Specification  This link exits the ClinicalTrials.gov site
Identifier: 106464
For additional information about this study please refer to the GSK Clinical Study Register
Informed Consent Form  This link exits the ClinicalTrials.gov site
Identifier: 106464
For additional information about this study please refer to the GSK Clinical Study Register
Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: 106464
For additional information about this study please refer to the GSK Clinical Study Register
Clinical Study Report  This link exits the ClinicalTrials.gov site
Identifier: 106464
For additional information about this study please refer to the GSK Clinical Study Register
Statistical Analysis Plan  This link exits the ClinicalTrials.gov site
Identifier: 106464
For additional information about this study please refer to the GSK Clinical Study Register
Study Protocol  This link exits the ClinicalTrials.gov site
Identifier: 106464
For additional information about this study please refer to the GSK Clinical Study Register

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00380393     History of Changes
Other Study ID Numbers: 106464
First Submitted: September 25, 2006
First Posted: September 26, 2006
Last Update Posted: October 12, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Keywords provided by GlaxoSmithKline:
Malaria
Plasmodium
RTS
S/AS01
Falciparum

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs